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Abstract
Purpose There is a large body of evidence supporting the
efficacy of low level laser therapy (LLLT), more recently
termed photobiomodulation (PBM), for the management of
oral mucositis (OM) in patients undergoing radiotherapy
for head and neck cancer (HNC). Recent advances in
PBM technology, together with a better understanding of
mechanisms involved, may expand the applications for
PBM in the management of other complications associated
with HNC treatment. This article (part 1) describes PBM
mechanisms of action, dosimetry, and safety aspects and,
in doing so, provides a basis for a companion paper (part
2) which describes the potential breadth of potential appli-
cations of PBM in the management of side-effects of
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(chemo)radiation therapy in patients being treated for HNC
and proposes PBM parameters.
Methods This study is a narrative non-systematic review.
Results We review PBM mechanisms of action and dosi-
metric considerations. Virtually, all conditions modulated
by PBM (e.g., ulceration, inflammation, lymphedema,
pain, fibrosis, neurological and muscular injury) are
thought to be involved in the pathogenesis of
(chemo)radiation therapy-induced complications in patients
treated for HNC. The impact of PBM on tumor behavior
and tumor response to treatment has been insufficiently
studied. In vitro studies assessing the effect of PBM on
tumor cells report conflicting results, perhaps attributable
to inconsistencies of PBM power and dose. Nonetheless,
the biological bases for the broad clinical activities as-
cribed to PBM have also been noted to be similar to those
activities and pathways associated with negative tumor be-
haviors and impeded response to treatment. While there
are no anecdotal descriptions of poor tumor outcomes in
patients treated with PBM, confirming its neutrality with
respect to cancer responsiveness is a critical priority.
Conclusion Based on its therapeutic effects, PBM may have
utility in a broad range of oral, oropharyngeal, facial, and neck
complications of HNC treatment. Although evidence suggests
that PBM using LLLT is safe in HNC patients, more research
is imperative and vigilance remains warranted to detect any
potential adverse effects of PBM on cancer treatment out-
comes and survival.
Keywords Low level laser therapy . Low level light therapy .
Photobiomodulation .Mucositis . Orofacial complications .
Chemotherapy . Radiation therapy . Head and neck cancer .
Safety . LLLTand PBM
Introduction
Nearly all patients with advanced head and neck cancer (HNC)
suffer complications from treatment with radiation therapy (RT)
or chemoradiotherapy (CRT) [1]. CRT is currently the standard
of care with or without surgery in advanced HNC. An increased
frequency and severity of side effects is seen, particularly when
chemotherapy (CT) is combined with accelerated or
hyperfractionated RT regimens. It is now recognized that organ
preservation in HNC treatment is not synonymous with func-
tion preservation, and effects on quality of life (QoL) must be
considered in cancer treatment planning and extending survival
[2, 3].
RT to the head and neck, with or without CT, damages
adjacent tissues within the radiation field despite continuing
efforts to minimize these effects [1]. Furthermore, targeted
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therapies administered as single agents, and combined with
RT or CRT, may generate additional symptoms [4–6]. Acute
complications include oral mucositis (OM), pain, dysphagia,
infections, salivary changes, dysgeusia, and dermatitis.
Common chronic complications include hyposalivation and
xerostomia, mucosal infections, mucosal atrophy, neuropa-
thies including mucosal pain, dysgeusia, tooth demineraliza-
tion and rampant caries, progression of periodontitis, soft tis-
sue and/or bone necrosis, mucocutaneous and muscular fibro-
sis, dysphagia, trismus, lymphedema, dermatitis, and voice
and speech alterations [7]. These complications are associated
with morbidity and mortality, increased use of health care
resources and costs, and may compromise patient adherence
to cancer therapy protocols resulting in suboptimal outcomes.
Among the few supportive care measures available, low
level laser or light therapy (LLLT) has shown significant prom-
ise. LLLT refers to light therapy that may stimulate tissue re-
generation, reduce inflammation, and control pain. These treat-
ments were originally referred to as “low level laser” because
the light is of low intensity compared with other forms of med-
ical laser treatment, which are used for ablation, cutting, and
coagulation. At the 2014 joint North American Association for
Laser Therapy (NAALT) and World Association for Laser
Therapy (WALT) conference, photobiomodulation (PBM)
was accepted as the preferred name with the following defini-
tion: “The therapeutic use of light [e.g. visible, near infrared
(NIR), infrared (IR)] absorbed by endogenous chromophores,
triggering non-thermal, non-cytotoxic, biological reactions
through photochemical or photophysical events, leading to
physiological changes” [8].
The potential utility of PBM in the management
of side-effects of chemoradiation therapy in head and neck
cancer
Although the biological mechanisms underlying the therapeu-
tic effects of PBM have not been fully elucidated, studies sug-
gest that PBM enhances wound healing [9], significantly re-
duces inflammation, and prevents fibrosis [10–15]. Moreover,
PBM reduces pain and improves function [16–19]. These pho-
tobiological reactions have been shown to occur in various
tissues.
Systematic reviews have suggested efficacy of PBM for
OM management in hematopoietic stem cell transplant
(HSCT) recipients and in HNC patients [20–25]. Whereas in
most studies, PBM is applied intra-orally on the oral mucosal
tissues, studies indicate that it may also be administered extra-
orally, with a resultant effect on structures at risk for OM
transcutaneously, thereby enhancing the ease of delivery and
possibly the efficacy of treatment [23, 26].
In addition, new generation PBM devices consisting of a
cluster of laser or light-emitting diode (LED) beams, instead
of a single laser point, provide exposure of larger fields.
Monochromatic high-quality LED beams have the same prop-
erties as diode lasers with the same wavelength, but their light
beam is less coherent. LED specifics need to be carefully
matched to PBM using lasers when considering LED arrays.
When used with appropriate parameters, the light is able to
penetrate into tissues sufficiently to activate cellular processes
[27]. This finding suggests that extra-oral administration of
PBM (with or without concurrent use of intra-orally adminis-
tered PBM) enables the light to reach other anatomical struc-
tures of the head and neck at risk for RT- and CRT-induced
complications. This may broaden the range of indications for
PBM for the prevention and treatment of cancer treatment-
induced complications.
Goals of this work
A task force consisting of an international multidisciplin-
ary panel of clinicians and researchers with expertise in
the area of supportive care in cancer and/or PBM clinical
application and dosimetry was formed. The mission of
this group is to aid in the design of PBM study protocols,
identify validated outcome measures, and test the efficacy
and safety of PBM for the management of complications
related to cancer therapy.
In this paper, we review and discuss PBM mechanisms of
action, dosimetry, and safety considerations. In a subsequent
paper (part 2), we (i) identify selected oral, oropharyngeal,
facial, and neck complications of treatment for HNC, in which
PBMmay have potential for prophylaxis and/or treatment; (ii)
propose PBM parameters for prophylaxis and therapy to mit-
igate these complications based on current evidence and
knowledge; and (iii) discuss directions of future research re-
lated to the use of PBM in HNC.
PBM mechanisms of action and therapeutic effects
The conclusion that PBM effectively modulates biological
function is supported by a plethora of clinical and laboratory
studies [17, 28]. Despite variations in instrumentation and
dosing parameters, since its introduction in 1967, PBM has
been shown to enhance wound repair and tissue regeneration
by influencing different phases of injury resolution including
the following: (i) the inflammatory phase, in which immune
cells migrate to the site of tissue injury, ii) the proliferative
phase, which includes stimulation of fibroblasts and macro-
phages as well as other repair components, and iii) the remod-
eling phase, consisting of collagen deposition and rebuilding
of the extracellular matrix at the wound site [29].
Although the complex biological mechanisms underlying
the therapeutic effects of PBM have not been completely elu-
cidated and may vary among different cell types and tissue
states (healthy versus stressed or hypoxic), laboratory and
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clinical studies suggest that PBM significantly reduces inflam-
mation and prevents fibrosis [10–15]. It has become increas-
ingly clear that PBM’s biological effects are closely dose-re-
lated. In fact, the historical lack of dosing consistency has
been a confounder in the comprehensive interpretation of
PBM activity. Nonetheless, confirmatory studies have contrib-
uted to a fundamental understanding of PBM biology.
Current data suggest that PBM acts predominantly on cy-
tochrome c oxidase (CcO) in the mitochondrial respiratory
chain by facilitating electron transport resulting in an in-
creased transmembrane proton gradient that drives adenosine
triphosphate (ATP) production [30]. ATP is the universal en-
ergy source in living cells essential for all biologic reactions,
and even a small increase in ATP levels can enhance bioavail-
ability to power the functions of cellular metabolism [31]. In
addition, the absorption of red or NIR light may cause a short,
transient burst of reactive oxygen species (ROS) that is
followed by an adaptive reduction in oxidative stress. This
action, impairment of ROS production, has been shown to
favorably mitigate radiation-induced injury and mimics the
activity of molecular agents that attenuate tissue damage (ex-
amples include amifostine, N-acetyl cysteine, and superoxide
dismutase).
Low concentrations of ROS impact many cellular process-
es, including activation of key transcription factors such as
nuclear factor kappa B (NF-κB). This results in the expression
of stimulatory and protective genes [32], which generate
growth factors belonging to the fibroblast growth factor fam-
ily, pro-inflammatory cytokines, and chemokines that are in-
volved in tissue repair.
In hypoxic or otherwise stressed cells, mitochondria pro-
duce nitric oxide (mtNO), which binds to CcO and displaces
oxygen [33]. This binding results in inhibition of cellular res-
piration, decreased ATP production, and increased oxidative
stress (a state that develops when the levels of ROS exceed the
defense mechanisms), leading to the activation of intracellular
signaling pathways, including several transcription factors
[34]. These include redox factor-1 (Ref-1), activator protein-
1 (AP-1), NF-κB, p53, activating transcription factor/cAMP-
response element–binding protein (ATF/CREB), hypoxia-
inducible factor (HIF)-1, and HIF-like factor [35]. These tran-
scription factors induce downstream production of both in-
flammatory mediators, such as tumor necrosis factor-alpha
(TNF-α), interleukin (IL)-1 and IL-6, cyclooxygenase
(COX)-2, and prostaglandin E2 (PGE-2) [34, 36, 37] and
anti-inflammatory mediators [transforming growth factor
(TGF)-beta, IL-10]. There is evidence suggesting that when
PBM is administered with appropriate parameters to stressed
cells, NO is dissociated from its competitive binding to CcO,
ATP production is increased, and the balance between proox-
idant and antioxidant mediators is restored, resulting in a re-
duction of oxidative stress [38]. For example, PBM has been
shown to attenuate the production of ROS by human
neutrophils [39]. Silveira et al. [40] reported that PBM re-
duced ROS in an animal model of traumatic tissue injury,
whereas a study in a model of acute lung inflammation found
PBM to reduce the generation of TNF-α and to increase IL-10
[41]. In addition, NO is a potent vasodilator [42] and can
increase the blood supply to the light illuminated tissue.
PBM-mediated vascular regulation increases tissue oxygena-
tion and also allows for greater traffic of immune cells, which
may contribute to the promotion of wound repair and regen-
eration [34].
Moreover, PBM, when delivered appropriately, reduces
pain and improves function [19, 30–32]. In addition, in vivo
studies show that PBM is neuroprotective and may benefit
neurodegenerative diseases and neurotrauma [33, 34].
Analgesic effects are probably induced by additional mecha-
nisms rather than by the increased ATP/reduced oxidative
stress model. PBM with a relatively high power density (>
300 mW/cm2), when absorbed by nociceptors, has an inhibi-
tory effect on A and C neuronal pain fibers. This slows neural
conduction velocity, reduces amplitude of compound action
potentials, and suppresses neurogenic inflammation [19].
Preliminary studies suggest that multiple conditions that
may play a role in the pathogenesis of RT- and CRT-induced
complications in patients treated for HNC (e.g., ulceration,
inflammation, lymphedema, pain, fibrosis, neurological and
muscular injury) may be modulated by PBM. For example,
in an animal model of OM, it was demonstrated that PBM
decreased COX-2 expression [43] and decreased the number
of neutrophils in the inflammatory infiltrate [44].Moreover, in
the chronic sequelae of RT and CRT, an excessive fibroblastic
response is hypothesized to be related to acute oxidative inju-
ry, with resulting cell damage, ischemia, and an ongoing in-
flammatory response resulting in fibrosis [45]. The critical
difference between normal wound healing and fibrosis devel-
opment appears to be, that in fibrosis, signaling pathways
escape normal cellular regulation [46]. Reduction of fibrosis
could be mediated by the beneficial effects of PBM on the
oxidant/antioxidant balance [47], downregulation of TGF-β,
and inhibition of excessive fibroblast proliferation [48].
Although most studies have demonstrated efficacy in man-
agement of both acutely and chronically affected tissues, not
all PBM investigations have yielded positive outcomes. As
discussed below, these divergent results may be attributed to
several factors, most importantly dosimetry. Clearly, more in-
vestigation at the molecular, cellular, and tissue level is needed
to fully understand the complexity of PBM function.
PBM parameters
PBMparameters have beenmostly reportedwithin the red and
NIR wavelength range of 600–1000 nm, with a power density
of between 5 and 150 mW/cm2 and are typically applied for
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30–60 s per point. The therapeutic effect is dictated by the
energy density measured in joule per centimeter squared.
Commonly reported PBM devices include helium-neon
(HeNe) gas laser, gallium–arsenide (GaAs), neodymium-
doped yttrium aluminum garnet (Nd:YAG), gallium alumi-
num arsenide (GaAlAs), indium gallium aluminum phosphide
(InGaAlP) diode lasers, non-thermal, non-ablative carbon di-
oxide (CO2) lasers, LED arrays, and visible light.
The PBM effects on the exposed tissues depend on the fol-
lowing: cell type, redox state of the cell, irradiation parameters
(including wavelength, power density), and time of exposure
[23, 49]. A biphasic dose response has been shown, which un-
derlines that there are optimal irradiation and dose parameters,
although these will likely vary according to underlying patholo-
gy (cellular layers and depth from the surface of application),
mucosal surface or skin, and individual patient-associated factors
[50]. Bearing in mind, dosage lower than the optimal value may
have a diminished effect, while doses higher than optimal can
have negative therapeutic outcomes [34, 49].
Thus, for PBM to be effective, the irradiation parameters,
including the energy delivered, power density, pulse structure,
delivery to the appropriate anatomical location (operator-de-
pendent effect), and appropriate treatment timing and repeti-
tion, need to be within the biostimulatory dose windows [22,
34, 49, 51, 52].
Titrating adequate doses and defining the other required
PBM parameters according to evidence gathered in a system-
atic manner for each indication is a prerequisite for treatment
success. Without standardization in beam measurement, dose
calculation, and the correct reporting of these parameters, stud-
ies will not be reproducible, and outcomes will not be consis-
tent. A common misconception is that wavelength and energy
(in J) or energy density (J/cm2) are all that is necessary in order
to replicate a successful treatment and that the original power,
power density, and duration parameters do not matter [53, 54].
A checklist to help researchers understand and report all the
necessary parameters for a reproducible scientific study has
been developed (Table 1) [54]. PBM devices are manufactured
depending on “class” of laser device with multiple options to
control the above dosimetry. However, it is not uncommon to
find discrepancies between the specifications provided by a
device manufacturer and the actual performance of the device
[55]. Therefore, device maintenance including power measure-
ments should be carried out regularly during research trials and
also in clinical practice.
Potential effects of PBM on tumor
The first prerequisites for any potential agent to be used to
prevent cancer regimen-related complications are that it does
not adversely affect tumor risk, tumor behavior, or tumor re-
sponse to treatment.
Given the breadth of PBM’s biology, there exists a signif-
icant opportunity and it is imperative to establish its tumor-
related neutrality, or even the possibility that PBM might pro-
vide an adjunctive therapy when used with conventional
modes of anti-cancer treatment. As noted below, currently,
there are more questions than answers. Although it seems
highly unlikely (both teleologically and based on available
data) that PBM in itself poses a carcinogenic threat, its poten-
tial to alter established tumor behaviors such as proliferation
or invasion may not be trivial [56]. We do know that PBM
effectively activates a sweeping range of pathways and medi-
ators which have been implicated in tumor conduct. Thus,
opportunities for pre-clinical and clinical research abound.
Molecular biology
Significant progress has been made in the past decade in our
understanding of the molecular biology which drives head and
neck squamous cell carcinoma (SCC) and the mechanisms of
action of PBM.
PI3K/AKT/mTOR signaling pathway
Activation of the PI3K/AKT/mTOR pathway is associated
with many of the activities that may be associated with
PBM’s favorable impact on wound healing: cell survival, mi-
gration, proliferation, and angiogenesis. Yet PI3K/AKT/
mTOR signaling is also among commonly dysregulated path-
ways associated with cancer, including head and neck SCC
[57], and its activation has been reported to promote the ac-
quisition of epithelial-mesenchymal transition, cancer stem
cell phenotypes, and cancer radioresistance [58]. Conversely,
inhibition of the pathway has been viewed as a potential strat-
egy to increase radiation sensitivity of tumor cells [59].
Recently reported data suggest that the migration of oral
keratinocytes to occur following PBM is attributable to acti-
vation of the AKT/mTOR signaling pathway [60].
Consequently, the observation reported by Sperandio et al.
[61] that PBM modified the expression of proteins related to
the progression and invasion of oral cancer cell lines suggests
that PBM activation of the AKT/mTOR signaling pathway
may be undesirable. The lack of data from in vivo models or
patients leaves open the question on the breadth of PBM ef-
fects on malignant cells and non-malignant tissue. For exam-
ple, assuming AKT/mTOR is activated by PBM, would tumor
tissue be affected if it was distant from the site of application,
i.e. treating the mouth for OM in an individual being treated
for a hypopharyngeal cancer?
TGF-β signaling pathway
TGF-β has potentially contradictory roles relative to tumor
behavior [62]. While its tumor suppressive effects are notable
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in the early stages of carcinogenesis, it may promote growth
and spread of established tumors. Through serine/threonine
kinases and Smad effectors, TGF-β can act as a tumor sup-
pressor by inhibiting proliferation and inducing apoptosis
[63]. Conversely, it may be overproduced by human tumors
and is associated with induction of epithelial-mesenchymal
transition, the prelude to tumor invasiveness, angiogenesis,
suppression of elements of immune surveillance, and recruit-
ment of signaling pathways that may facilitate metastases
[64]. Additionally, it appears that TGF-β1 signaling may en-
hance tumor progression by altering the surrounding stroma
through Smad signaling [65]. Thus, the observation that PBM
stimulates TGF-β/Smad signaling pathway [66] could be
viewed as a double-edge sword depending on when and what
tissue was exposed [67].
MAPK pathways
Mitogen-activated protein kinase (MAPK) pathways play a
significant role in cancer [68]. Among the MAPK pathways,
perhaps the best studied relative to cancer is the ERK pathway.
ERK signaling is associated with a number of tumor
Table 1 Photobiomodulation (PBM) parameters to be reported in clinical studies. Adapted from [54]
Category Parameter Unit Explanation
Irradiation
parameters
Wavelength Nanometer (nm) Light is packets of electromagnetic energy called photons that sometimes
behave like particles but also have a wave-like property. Wavelength
determines which chromophores will absorb the light. Light is visible
in the 400–700-nm range. The energy of each photon is greater at
short wavelengths than longer wavelengths; e.g., red light is ~2
elektronvolt (ev) per photon and blue light is ~3 ev.
Power Watt (W) The number of photons per second. The higher the power the more
photons emitted every second.
Beam area Centimeter squared
(cm2)
The surface area of the beam on the patient. Also known as spot size. This
is not always easy to determine because laser beams are usually more
intense in the middle then fade towards the edge (Gaussian distribution)
so it is hard to define where the exact edge of the beam is without special
instruments. Many research authors do not report this parameter, let
alone report it correctly.
Aperture size Centimeter squared
(cm2)
The area of the light source tip. This is not necessarily identical as the beam
area. The difference between the aperture size and beam area will be
determined by the beam divergence and distance of the light source tip
from the tissue.
Irradiance (power density,
or intensity)
Watts per centimeter
squared (W/cm2)
Power (W) ÷ beam area (cm2). More irradiance could allow less treatment
time; however, many studies have shown that if the irradiance is too
high, treatment can be less effective even if the same total dose is
delivered. The treatment guidelines suggest the safe and effective
irradiance ranges.
(Radiant) Energy Joules (J) Power (W) × time (s). More power could mean less treatment time;
however, many studies have shown that too much power is less effective
even if the same total energy is delivered. The treatment guidelines
suggest the safe and effective energy ranges.
Time Second (s) How long each treatment is applied at each location.
Dosage (fluence or
energy density)
Joules per centimeter
squared (J/cm2)
Energy (J) ÷ beam area (cm2), or power (W) ÷ beam area (cm2)
× time (s). Different outcomes can be obtained if the total dosage
is delivered with high energy and short time or low energy and long
time.
Operating mode Continuous wave
(CW), pulsed
The continuity of the production of the output beam may be continuous
or pulsed. There are several types of pulsed beam.
Pulse structure Second (s) The durations of the pulse being on or off.
Treatment
parameters
Physical relationship
to the organ
Applicable when there is more than one way to approach the organ. For
example, intra-oral device versus extra-oral device.
Timing Time of the treatment session relative to the cancer treatment.
Treatment schedule The frequency of treatments per day/week and the total number of
treatments.
Anatomical location The anatomical site that was exposed to the light beam. If multiple
locations were treated, all need to be described.
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behaviors. Of relevance to HNC is a correlation of its expres-
sion with increased epithelial growth factor receptor (EGFR)
[69]. The ERK pathway also impacts vascular epithelial
growth factor (VEGF) expression and its consequent angio-
genesis. While angiogenesis may be desirable from a wound
healing perspective, the finding that PBM stimulates EGFR
and VEGF production through ERK signaling may be a con-
cern in a tumor environment [70, 71].
Heat shock proteins and microRNAs
The robust biological effects of PBM are borne out by the
observations of its ability to stimulate a range of biological
processes including upregulation of heat shock proteins (HSP)
[72] and microRNAs [73]. Relative to the current discussion,
HSP is essential for cancer survival and has been identified as
a potential target for anti-cancer therapy.
While the number of miRNAs that are upregulated follow-
ing PBM is substantial, of particular note is the finding that
mi126 is among the list as endogenous mi126 has been report-
ed to be associated with metastatic progression [74].
Molecular pathways with a potentially favorable effect
While the information above raises questions about possible
undesirable effects of PBM on tumor progression and re-
sponse to anti-cancer treatment, some observations suggest
that PBM might favorably impact tumor behavior through
its effects on vimentin expression, MyD88-dependent signal-
ing, reduction in TLR-4, and downregulation of NF-κB [75].
Furthermore, upregulation of ATP signaling by PBM may
promote apoptosis, as well as differentiation of tumor cells,
thereby slowing tumor proliferation [30, 76].
PBM effects on tumor cell lines
The effects of PBM on cell proliferation and differentiation
have been investigated in vitro using malignant cell lines,
which have generated conflicting data across a range of dif-
ferent tumor cell lines and PBM parameters [77–81]. For ex-
ample, Kreisler and coworkers reported proliferation of laryn-
geal carcinoma cells after 809 nm GaAIAs laser irradiation at
energy densities between 1.96 and 7.84 J/cm2 [78]. Werneck
and coworkers also found increased cell proliferation of HEp2
carcinoma cells after PBM exposure at different wavelengths
(685 and 830 nm) and doses [82]. In a study comparing PBM
administered to normal osteoblasts and to osteosarcoma cells
with a range of different wavelengths and doses, only 10 J/cm2
from an 830 nm laser was able to enhance osteoblast prolifer-
ation, whereas energy densities of 1, 5, and 10 J/cm2 from a
780-nm laser decreased proliferation. Osteosarcoma cells
were unaffected by 830 nm laser irradiation, whereas
670 nm laser had a mild proliferative effect [83]. An in vitro
study compared the effects of different doses of PBM at var-
ious wavelengths on human breast carcinoma and melanoma
cell lines [84]. Although certain doses of PBM increased
breast carcinoma cell proliferation, multiple exposures had
either no effect or showed negative dose response relation-
ships. PBM (wavelength 660 nm) administered in low doses
(1 J/cm2) increased in vitro proliferation and potentially in-
creased invasive potential of tongue SCC cells [56]. Similarly,
another in vitro study suggested that PBM (660 or 780 nm,
40 mW, 2.05, 3.07, or 6.15 J/cm2) may stimulate oral dysplas-
tic and cancer cell lines [61].
In contrast, a decreased mitotic rate was found in gingival
SCC after PBM at 805 nm and energy density of 4 and 20 J/
cm2 [80], whereas no effect on cell proliferation or protein
expression of osteosarcoma cells was found when PBM was
administered with a wavelength of 830 nm [85]. PBM
(808 nm; 5.85 and 7.8 J/cm2) had an inhibitory effect on the
proliferation of a human hepatoma cell line [86], and Sroka
et al. [87] reported that glioblastoma/astrocytoma cells exhib-
ited a slightly decreased mitotic rate after PBM at 805 nm and
5–20 J/cm2. Similarly, 808-nm laser irradiation with an energy
density of more than 5 J/cm2 inhibited cell proliferation of
glioblastoma cells in vitro [88]. Moreover, Al Watban et al.
[89] observed growth inhibition of cancer cell lines at relative-
ly high cumulative PBM doses. This prompted Crous and
Abrahamse [90] to hypothesize that PBM may have a thera-
peutic potential in lung cancer.
Protective effects of PBM against cytotoxic therapy
There are no data to suggest that PBM may protect cancer
cells against the cytotoxic effects of RT. On the contrary,
Schartinger et al. [91] observed a pro-apoptotic effect of
PBM in head and neck SCC cells, whereas no anti-apoptotic
effects occurred that might promote tumor cell resistance to
cancer therapy. Increased apoptosis of human osteosarcoma
cells was also induced by the administration of NIR (810 nm,
continuous wave, 20 mW/cm2, 1.5 J/cm2) prior to NPe6-
mediated photodynamic therapy as a result of increased cellu-
lar ATP and a higher uptake of the photosensitizer [92].
Recently, it was reported that PBM administered to normal
human lymphoblasts and leukemia cells prior to RT, resulted
in a differential response of normal versus malignant cells
suggesting that PBM does not confer protection and may even
sensitize cancer cells to RT-induced killing [93]. Nevertheless,
in vivo and clinical studies are warranted before firm conclu-
sions can be drawn.
Carcinogenic effects of PBM on normal cells
It seems unlikely that PBM has carcinogenic effects on normal
cells. The non-ionizing wavelengths of the red and NIR spec-
trum used in PBM are far longer than the safety limit of
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320 nm for DNA damage [94]. No signs of malignant trans-
formation in non-malignant epithelial cells and fibroblasts
were observed following exposure to PBMwith a wavelength
of 660 nm, 350 mW for 15 min during 3 consecutive days
[91]. In addition, no malignant transformation of normal
breast epithelial cells was detected in an in vitro study com-
paring the effects of different doses and wavelengths of PBM
during multiple exposures [84].
Data derived from in vivo and clinical studies
PBM (660 nm, 30 mW, 424 mW/cm2, 56.4 J/cm2, 133 s, 4 J),
applied to chemically induced SCC in hamster cheek pouch
tissue, increased tumor growth [95]. PBM at a dose of 150 J/
cm2 appeared safe, with only minor effects on B16F10 mela-
noma cell proliferation in vitro, and had no significant effect
on tumor growth in vivo. Only a high power density (2.5 W/
cm2) combined with a very high dose of 1050 J/cm2 could
induce melanoma tumor growth in vivo [96]. In a mouse
model to study PBM effects on UV-induced skin tumors, the
experimental mice received full body 670 nm PBM delivered
twice a day at 5 J/cm2 for 37 days, whereas controls received
sham PBM [97]. No enhanced tumor growth was observed,
whereas there was a small but significant reduction in tumor
area in the PBM group, potentially related to a local photody-
namic effect or PBM-induced antitumor immune activity.
Schaffer et al. [98] observed that PBM increased the
locoregional blood flow that contributed to better local oxygen-
ation and hypothesized that PBM applied shortly before cancer
treatment might enhance the effect of ionizing RT and local
delivery of chemotherapy. A recent randomized controlled trial
in which PBM was administered for prevention of OM during
CRT in HNC patients (diagnosed with SCC of the nasophar-
ynx, oropharynx, or hypopharynx) reported that at a median
follow-up of 18 months (range 10–48 months), patients treated
with PBM had better locoregional disease control and im-
proved progression-free or overall survival [99].
Current evidence suggests that PBM in the red or NIR
spectrum, with an energy density of 1–6 J/cm2 is safe and
effective. However, as with drug-based therapies for compa-
rable indications, disciplined follow-up studies in which sub-
ject cohorts large enough to represent the HNC tumor popu-
lation with respect to gender, tobacco and alcohol use, human
papilloma virus (HPV) status, primary stage, tumor therapy,
and variations in PBM dose and fields are needed to definitely
conclude that PBM fails to negatively impact survival and
progression-free survival.
Discussion and concluding remarks
PBM mechanisms have not been fully elucidated, but based
on its recognized therapeutic effects, PBMmay have utility in
a broad range of oral, oropharyngeal, facial, exocrine glands,
and neck complications of HNC treatment.
Titrating adequate doses and defining the other required
PBM parameters according to evidence gathered in a system-
atic way for each indication is a prerequisite for a successful
use of this technique. Without standardization in beam mea-
surement, dose calculation, and the correct reporting of these
parameters, studies will not be reproducible, and outcomes
will not be consistent.
There are no known significant adverse side effects for
PBM (administered with parameters discussed in more detail
in part 2) in HNC patients. However, the potential effect on
residual and new dysplastic and malignant cells has not been
definitively resolved. Virtually, all studies have focused on
cell-based assays rather than conventional xenograft or
orthotopic animal models. And the results of in vitro investi-
gations have been largely dependent on the experimental de-
sign and selection of target cells.
The lack of consistent findings and/or the latitude of inter-
pretation of the clinical significance of molecular biology
findings hampermeaningful conclusions. Continuing research
addressing the molecular pathways affected by PBM is
necessary.
It seems unlikely that PBM has carcinogenic effects on
normal cells or protects to cytotoxic effects of RT; there is
even some evidence suggesting that PBM may enhance treat-
ment response.
Studies indicate that different tumor cells have distinct re-
sponses to specific PBM parameters and doses. In part, these
differences may be also explained by variations in the cellular
microenvironment, since these have been shown to affect cel-
lular signal transduction pathways to PBM exposure [100].
The microenvironment of tumor cells varies among in vitro
studies and differs significantly from that found in animal
models. Moreover, this difference implies that the potential
of PBM to enhance proliferation of tumor cells in vitro does
not necessarily translate into harmful effects of PBM in cancer
patients. However, more research is necessary and vigilance
remains warranted to detect any potential adverse effects of
PBM on cancer treatment outcomes and survival [101].
In the part 2 of this paper, we will identify acute and chron-
ic complications associated with HNC therapy and review the
literature relevant to the potential use of PBM for the manage-
ment of these complications. PBM irradiation and dosimetric
ranges, which are potentially effective for these complications,
will be proposed. These parameters are intended to provide
guidance for well-designed future studies.
Disclaimer
This article is based on a narrative review of existing data and
the clinical observations of an international multidisciplinary
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panel of clinicians and researchers with expertise in the area of
supportive care in cancer and/or PBM clinical application and
dosimetry. This article is informational in nature. As with all
clinical materials, this paper should be used with the clear
understanding that continued research and practice could re-
sult in new insights and recommendations. The review reflects
the collective opinion and as such does not necessarily repre-
sent the opinion of any individual author. In no event shall the
authors be liable for any decision made or action taken in
reliance on the proposed protocols.
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